Compounds of Formula (I): wherein: R<1> is methoxymethyl; R<2> is selected from -C(O)NR<4>R<5>, -SO2NR<4>R<5>, -S(O)pR<4> and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R<3> is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R<4> is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R<5> is hydrogen or (1-4C)alkyl; or R<4> and R<5> together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; mis 0 or1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described. |